Last reviewed · How we verify

RedHill Biopharma Limited — Portfolio Competitive Intelligence Brief

RedHill Biopharma Limited pipeline: 0 marketed, 0 filed, 4 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 4 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
RHB-104 RHB-104 phase 3 Antibiotic combination Mycobacterium avium subspecies paratuberculosis (MAP) Gastroenterology / Immunology
RHB-102 RHB-102 phase 3 Gastric motility agent Ghrelin receptor Gastrointestinal
RHB-105 RHB-105 phase 3 Antiviral combination therapy Infectious Diseases
Rifamycin SV MMX Rifamycin SV MMX phase 3 Ansamycin antibiotic Bacterial RNA polymerase Gastroenterology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Beijing 302 Hospital · 1 shared drug class
  2. Brooke Army Medical Center · 1 shared drug class
  3. CCTU · 1 shared drug class
  4. Casa Sollievo della Sofferenza IRCCS · 1 shared drug class
  5. GlaxoSmithKline · 1 shared drug class
  6. HK inno.N Corporation · 1 shared drug class
  7. Halmstad County Hospital · 1 shared drug class
  8. Assistance Publique - Hôpitaux de Paris · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for RedHill Biopharma Limited:

Cite this brief

Drug Landscape (2026). RedHill Biopharma Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/redhill-biopharma-limited. Accessed 2026-05-16.

Related